This document has been prepared in accordance with accounting principles and practices generally accepted in Japan, and translated for reference only from the original Japanese version. The Company gives no warranty with respect to its correctness.
The original disclosure in Japanese was released on Feb. 10, 2022
Takara Holdings Inc.
Notice Concerning the Revision of Consolidated Business Results Forecast and Dividend Forecast (Increased Dividend) for the Fiscal Year Ending March 31, 2022
Takara Holdings Inc. (hereinafter the “Company”) hereby announces that it will revise the consolidated business results forecast and the dividend forecast for the fiscal year ending March 31, 2022 (from April 1, 2021 to March 31, 2022) released on November 9, 2021, as stated below. These revisions are based on consideration of recent performance trends.
1. Revision of the business results forecast
(1) Revised figures for the consolidated business results forecast for the fiscal year ending March 31, 2022 (from April 1, 2021 to March 31, 2022)
| (Millions of yen / %) |
|
|
(2) Reason for revision
For the fiscal year ending March 31, 2022, overall consolidated net sales are expected to exceed the previous forecast (announced on November 9, 2021) and reach a record high. This is because net sales for Takara Shuzo will be almost as expected; the eating and drinking establishment market has been performing favorably for Takara Shuzo International Group; and net sales of PCR testing-related products for COVID-19 and general research reagents are expected to be higher than the previous forecast for Takara Bio Group.
In terms of profit, operating income, ordinary income, and net income attributable to owners of the parent are expected to exceed the previous forecast and are projected to be an all-time high, with higher gross profit due to the increase in net sales and a decrease in the cost of sales ratio.
For further details of forecasts for each business segment, please refer to pages 12/20-15/20 in “Supplement for the Consolidated Financial Statements for the Third Quarter Ended December 31, 2021,” announced today.
2. Revision of the dividend forecast
(1) Details of revision
|
|
(2) Reason for revision
The Company’s policy on shareholder returns is to continuously pay stable dividends with a payout ratio in the high 30’s% range in line with sustainable earnings growth. Based on this upward revision of the business forecast, the Company has revised the year-end dividend forecast for the fiscal year ending March 31, 2022 from the initial forecast of ¥29 to ¥35 per share, announced on November 9, 2021.
Further, today consolidated subsidiary Takara Bio Inc. (The First Section of Tokyo Stock Exchange, security code number: 4974) also announced revisions to forecasts and dividend forecasts for the fiscal year ending March 31, 2022.
* The above-mentioned forecasts have been prepared based on the information available as of the date of announcement of this document and could differ from the actual results, etc.
